Biocon Announces Launch of EYLEA® Interchangeable Biosimilar Yesafili™ While PGR Denied Institution JD Supra 18:53 Fri, 14 Aug
Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron’s Eylea® 2 mg Business Wire (Press Release) 12:07 Mon, 03 Aug
